KeithHazletonMDPhD
Pediatric Gastroenterology • Los Angeles, CAPediatric Hepatology and Liver Transplantation
Assistant Professor
Dr. Hazleton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-660-2450
Summary
- Dr. Keith Hazleton is a pediatric gastroenterologist and hepatologist in Los Angeles, CA and is affiliated with Children’s Hospital Los Angeles. He received his medical degree from Albert Einstein College of Medicine and has been in practice 8 years. He is experienced in pediatric gastroenterology, hepatology, cystic fibrosis, and microbiology.
Education & Training
University of ColoradoFellowship, Transplant Hepatology, 2019 - 2020- University of ColoradoFellowship, Pediatric Gastroenterology, 2015 - 2019
- University of ColoradoResidency, Pediatrics, 2013 - 2015
Albert Einstein College of MedicineClass of 2013
Certifications & Licensure
AZ State Medical License 2020 - 2025
CA State Medical License 2023 - 2025
CO State Medical License 2015 - 2021- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Gastroenterology
- American Board of Pediatrics Pediatric Transplant Hepatology
Publications & Presentations
PubMed
- 232 citationsLow diversity gut microbiota dysbiosis: drivers, functional implications and recovery.Michael Kriss, Keith Z. Hazleton, Nichole M. Nusbacher, Casey G. Martin, Catherine A. Lozupone
Current Opinion in Microbiology. 2018-08-01 - 52 citationsPlasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal ModelMaria B. Cassera, Keith Z. Hazleton, Emilio F. Merino, Nicanor Obaldia, Meng-Chiao Ho
Plos One. 2011-11-11 - 11 citationsMultiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal ...Barbara K Lomeli, Hal Galbraith, Jared Schettler, George A Saviolakis, Wael El-Amin
Antimicrobial Agents and Chemotherapy. 2019-12-20
Press Mentions
The AMA Does Not Speak for UsDecember 9th, 2016
Grant Support
- 4rd year Clinical FellowCystic Fibrosis Foundation2018–2019
- 1st and 2nd Year Clinical FellowCystic Fibrosis Foundation2015–2017
Professional Memberships
- Member
- American Association for the Study of Liver DiseaseMember
External Links
- LinkedInhttp://www.linkedin.com/in/keith-hazleton
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
